Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study
Chen-Hua Liu(National Taiwan University Hospital), Jia‐Horng Kao(National Taiwan University Hospital), Yi‐Hsiang Huang(First Hospital of Lanzhou University), Ming‐Lung Yu(National Sun Yat-sen University), C. Brooks-Rooney, Ching-Chu Lo(St. Martin de Porres Hospital), Wei-Wen Su(Changhua Christian Hospital), Qian Ma, Chi-Yi Chen(Chia-Yi Christian Hospital), Tsai-Yuan Hsieh(Tri-Service General Hospital), Pin-Nan Cheng(National Cheng Kung University Hospital), Jyh-Jou Chen(Chi Mei Medical Center), Chih-Lin Lin(Taipei City Hospital), Cheng‐Yuan Peng(China Medical University)
Cited by 10
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
|Annals of Internal Medicine|2016|364